Statements in which the resource exists.
SubjectPredicateObjectContext
pubmed-article:6436733rdf:typepubmed:Citationlld:pubmed
pubmed-article:6436733lifeskim:mentionsumls-concept:C0005767lld:lifeskim
pubmed-article:6436733lifeskim:mentionsumls-concept:C0002607lld:lifeskim
pubmed-article:6436733lifeskim:mentionsumls-concept:C0042291lld:lifeskim
pubmed-article:6436733lifeskim:mentionsumls-concept:C0879626lld:lifeskim
pubmed-article:6436733lifeskim:mentionsumls-concept:C0205178lld:lifeskim
pubmed-article:6436733lifeskim:mentionsumls-concept:C0392747lld:lifeskim
pubmed-article:6436733lifeskim:mentionsumls-concept:C0681842lld:lifeskim
pubmed-article:6436733pubmed:issue11lld:pubmed
pubmed-article:6436733pubmed:dateCreated1984-11-27lld:pubmed
pubmed-article:6436733pubmed:abstractTextValproic acid (VPA) was given to 24 epileptic patients who were already being treated with other antiepileptic drugs. A standardized loading dose of VPA was administered, and venous blood was sampled at 0, 1, 2, 3, and 4 hours. Ammonia (NH3) was higher in patients who, during continuous therapy, complained of drowsiness (7 patients) than in those who were symptom-free (17 patients), although VPA plasma levels were similar in both groups. By measuring VPA-induced changes of blood NH3 content, it may be possible to identify patients at higher risk of obtundation when VPA is given chronically.lld:pubmed
pubmed-article:6436733pubmed:languageenglld:pubmed
pubmed-article:6436733pubmed:journalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:6436733pubmed:citationSubsetAIMlld:pubmed
pubmed-article:6436733pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:6436733pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:6436733pubmed:statusMEDLINElld:pubmed
pubmed-article:6436733pubmed:monthNovlld:pubmed
pubmed-article:6436733pubmed:issn0028-3878lld:pubmed
pubmed-article:6436733pubmed:authorpubmed-author:ArnetoliGGlld:pubmed
pubmed-article:6436733pubmed:authorpubmed-author:MoroniFFlld:pubmed
pubmed-article:6436733pubmed:authorpubmed-author:TargioniGGlld:pubmed
pubmed-article:6436733pubmed:authorpubmed-author:ZappoliRRlld:pubmed
pubmed-article:6436733pubmed:authorpubmed-author:BaruzziAAlld:pubmed
pubmed-article:6436733pubmed:authorpubmed-author:ValenzaTTlld:pubmed
pubmed-article:6436733pubmed:authorpubmed-author:ZaccaraGGlld:pubmed
pubmed-article:6436733pubmed:authorpubmed-author:PaganiniMMlld:pubmed
pubmed-article:6436733pubmed:authorpubmed-author:CampostriniRRlld:pubmed
pubmed-article:6436733pubmed:issnTypePrintlld:pubmed
pubmed-article:6436733pubmed:volume34lld:pubmed
pubmed-article:6436733pubmed:ownerNLMlld:pubmed
pubmed-article:6436733pubmed:authorsCompleteYlld:pubmed
pubmed-article:6436733pubmed:pagination1519-21lld:pubmed
pubmed-article:6436733pubmed:dateRevised2006-11-15lld:pubmed
pubmed-article:6436733pubmed:meshHeadingpubmed-meshheading:6436733-...lld:pubmed
pubmed-article:6436733pubmed:meshHeadingpubmed-meshheading:6436733-...lld:pubmed
pubmed-article:6436733pubmed:meshHeadingpubmed-meshheading:6436733-...lld:pubmed
pubmed-article:6436733pubmed:meshHeadingpubmed-meshheading:6436733-...lld:pubmed
pubmed-article:6436733pubmed:meshHeadingpubmed-meshheading:6436733-...lld:pubmed
pubmed-article:6436733pubmed:meshHeadingpubmed-meshheading:6436733-...lld:pubmed
pubmed-article:6436733pubmed:meshHeadingpubmed-meshheading:6436733-...lld:pubmed
pubmed-article:6436733pubmed:meshHeadingpubmed-meshheading:6436733-...lld:pubmed
pubmed-article:6436733pubmed:meshHeadingpubmed-meshheading:6436733-...lld:pubmed
pubmed-article:6436733pubmed:meshHeadingpubmed-meshheading:6436733-...lld:pubmed
pubmed-article:6436733pubmed:meshHeadingpubmed-meshheading:6436733-...lld:pubmed
pubmed-article:6436733pubmed:year1984lld:pubmed
pubmed-article:6436733pubmed:articleTitleAcute changes of blood ammonia may predict short-term adverse effects of valproic acid.lld:pubmed
pubmed-article:6436733pubmed:publicationTypeJournal Articlelld:pubmed
pubmed-article:6436733pubmed:publicationTypeResearch Support, Non-U.S. Gov'tlld:pubmed